Prognostic Impact of Early Disease Progression and Early Mortality in Patients with Multiple Myeloma: A Real-World Cohort Study - Top-Institutions - MDSpire

Prognostic Impact of Early Disease Progression and Early Mortality in Patients with Multiple Myeloma: A Real-World Cohort Study

  • By

  • Vlaisavljević, Nada

  • Milosevic, Ivana

  • Sekulić, Borivoj

  • Nikolić, Jelena

  • Tomić, Velimir

  • Savić, Aleksandar

  • May 11, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology

  • #2

    Ottawa Hospital Research Institute
    Ottawa Hospital Research Institute

    Ottawa, ON

    Key Differentiators

    • Hematology

  • #3

    Institute for Clinical Evaluative Sciences
    Institute for Clinical Evaluative Sciences

    Toronto, ON

    Key Differentiators

    • Hematology

  • #4

    Washington University School of Medicine
    Washington University School of Medicine

    St. Louis, MO

    Key Differentiators

    • Hematology

  • #5

    McMaster University
    McMaster University

    Hamilton, ON

    Key Differentiators

    • Hematology

Original Source(s)

Prognostic Impact of Early Disease Progression and Early Mortality in Patients with Multiple Myeloma: A Real-World Cohort Study

  • by Vlaisavljević, Nada , Milosevic, Ivana , Sekulić, Borivoj , Nikolić, Jelena , Tomić, Velimir , Savić, Aleksandar

  • May 11, 2026

Related Content

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines

Patient Awareness, Attitudes, and Preventive Practices Related to Venous Thromboembolism in Multiple Myeloma: A Cross-Sectional Analysis

AstraZeneca Deepens China Cell Therapy Push

New Shanghai manufacturing base and innovation center will support CAR-T production and a broader UK-China life sciences collaboration

  • March 31, 2026

  • 2 min